Chronic Liver Disease and Hepatitis-B Antigen: A Prospective Study

Waes, Leen Van; Segers, J.; Egmond, J. Van; Nimmen, L. Van; Barbier, F; Wieme, R.J.; Demeulenaere, L

doi:10.1136/bmj.3.5928.444

Cited by 33 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings support prospect of survival than control patients, differences suggested by others (Bulkley et al, ising three HBsAg positive and 26 negative 1970; Finlayson et a!., 1972;Dudley et a!., 1973) ts who earlier received azathioprine or but not universally confirmed (Reed et al, 1973; o. Direct comparison of HBsAg positive Van Waes et al, 1974). As the incidence of such ts with or without prednisone was not feasible 'autoantibodies' failed fully to differentiate between ,e of the small number of HBsAg positive HBsAg positive and negative patients, and as ts on control therapy; however, the three weakly positive results were not infrequent in both g positive patients did not appear to have a groups, it appears likely that positivity of these HBsAj tests represents alterations in host response, rather than specific aetiologies.…”

Section: Discussionsupporting

confidence: 81%

Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen.

Schalm¹,

Summerskill²,

Gitnick³

et al. 1976

Gut

127

View full text Add to dashboard Cite

SUMMARY To determine the clinical implications of HBsAg in severe chronic active liver disease (CALD), patients with HB.Ag positive CALD were compared with those chosen by identical clinical, functional, and morphological criteria in whom this test and anti-HB5 were negative. HB8Ag positive patients were predominantly males over 40 years of age and more frequently failed to respond to conventional treatment programmes with prednisone. HBsAg negative patients were more often female and younger, had a higher incidence of associated immunopathic disease and immunoserological markers in high titre, and more often responded to treatment with full remission of their disease. HBsAg positive patients failing treatment with conventional doses of prednisone often improved with higher doses, but did not reach full remission of their disease. The benefit-risk ratio of both conventional and high doses of prednisone in HBsAg positive severe CALD needs further clarification.

show abstract

Section: Discussionsupporting

confidence: 81%

Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen.

Schalm¹,

Summerskill²,

Gitnick³

et al. 1976

Gut

127

View full text Add to dashboard Cite

show abstract

“…", l 2 Similar studies found a prevalence of hepatitis B surface antigenaemia of 48'3% and 46.2% in CPH. 12." The present study shows that 7/27 (26%) of our patients with CAH and 7/15 (47%) with CPH were HBsAg positive.…”

Section: Discussionsupporting

confidence: 47%

The Importance of Hepatitis B Infection in the Aetiology of Chronic Hepatitis: A Sydney Hospital Experience

McCaughan

Parsons

Bateyi

et al. 1982

Australian and New Zealand Journal of Medicine

View full text Add to dashboard Cite

The importance of hepatitis B infection in the aetiology of chronic hepatitis: a Sydney hospital experience. G. W. McCaughan, C. Parsons, R. G. Batey and N. D. Gallagher, Aust. N.Z. J. Med., 1982, 12, pp. 19–21. This is an analysis of the role of the hepatitis B virus as an aetiological factor in forty‐two patients with either chronic active or chronic persistent hepatitis. Hepatitis B surface antigenaemia was present in seven of 27 patients with chronic active and in seven of 15 with chronic persistent hepatitis. In patients without hepatitis B surface antigenaemia, other hepatitis B markers were found in seven patients although their presence was thought unlikely to have aetiological significance. This report suggests a substantial contribution of hepatitis B infection to the cause of chronic hepatitis in Sydney.

show abstract

“…In London at a specialist centre 58% of 65 cases of cirrhosis had HBsAg in the serum (Portmann et al, 1976), in Belgium 49% of 41 cases (van Waes et al, 1974), and in Iraq 58 % of 64 cases (Boxall et al, 1976). In London HBsAg was identified in the serum of0-3 % of 1489 control hospital patients by the relatively insensitive immunodiffusion method (Medical Research Council, 1974).…”

Section: Discussionmentioning

confidence: 99%